<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-046175
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090921
<ITEMS>1.01
<ITEMS>9.01
<FILING-DATE>20090925
<DATE-OF-FILING-DATE-CHANGE>20090925
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>RXI PHARMACEUTICALS CORP
<CIK>0001390478
<ASSIGNED-SIC>2834
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33958
<FILM-NUMBER>091088136
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
<PHONE>508-767-3861
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b77383e8vk.htm
<DESCRIPTION>RXI PHARMACEUTICALS CORPORATION
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(D) OF THE<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): September&nbsp;21, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><font style="border-bottom: 1px solid #000000"><B>RXI PHARMACEUTICALS CORPORATION</B></font>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">001-33958
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">20-8099512</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">60 Prescott Street, Worcester, MA 01605</DIV>

<DIV align="center" style="font-size: 10pt"><font style="border-top: 1px solid #000000">(Address of Principal Executive Offices) (Zip Code)</font></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Registrant&#146;s telephone number, including area code: (508)&nbsp;767-3861</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions
(<I>see </I>General Instruction A.2. below):
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act
(17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act
(17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">










<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On September&nbsp;21, 2009, RXi Pharmaceuticals Corporation (the &#147;Company&#148;) entered into a Patent and
Technology Assignment Agreement with Advirna, LLC (&#147;Advirna&#148;), a Colorado limited liability company
co-founded by Anastasia Khvorova, Chief Scientific Officer of the Company. Pursuant to the terms
of the agreement, Advirna assigned to the Company certain patent and technology rights related to
chemically modified polynucleotides (the &#147;Rights&#148;) and the Company granted to Advirna a fully paid-up license to the Rights in a specified field.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Under the terms of the agreement, the Company will pay to Advirna an annual maintenance fee
beginning on January&nbsp;1, 2011, certain payments upon the achievement of regulatory milestones and
royalty payments on the sales of certain products. The agreement will terminate upon the earlier
of (x)&nbsp;the expiration of the last to expire of the patent rights included in the agreement and (y)
the abandonment of the last to be abandoned of any patents included in the agreement, but either party may terminate the
agreement upon written notice of a material breach by the other party, subject to certain cure provisions and restrictions. In addition, the Company may terminate the agreement upon 90 days&#146;
prior written notice to Advirna and Advirna may terminate upon 90 days&#146; prior written notice to the
Company in the event the Company ceases to use reasonable efforts to research, develop,
license or otherwise commercialize the Rights.  If the agreement expires in accordance with its terms or is terminated by a party in the absence of a material breach or for cause in the event that the Company fails to pay Advirna certain fees, the Company will assign the Rights back to Advirna.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s press release announcing the agreement is filed as Exhibit&nbsp;99.1 to this Current
Report on Form 8-K, and is incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of RXi Pharmaceuticals Corporation dated September&nbsp;25, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Signature</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">RXI PHARMACEUTICALS CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: September  25, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
Tod Woolf</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Tod Woolf&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Index to Exhibits
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press release of RXi Pharmaceuticals Corporation dated September&nbsp;25, 2009</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>b77383exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE OF RXI PHARMACEUTICALS CORPORATION DATED SEPTEMBER 25, 2009
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="b77383b7738301.gif" alt="(RXI PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RXi Pharmaceuticals Obtains Direct Ownership of Previously Licensed RNAi<BR>
Delivery Intellectual Property</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Strengthens Position in RXi Proprietary Self-delivering rxRNA&#153;</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Worcester, MA, September&nbsp;25, 2009 &#151; </B>RXi Pharmaceuticals Corporation (Nasdaq: RXII), a
biopharmaceutical company pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct
ownership of technology for which it had previously exercised its option to exclusively license
from Advirna LLC. The novel acquired technologies potentially enable <I>in vivo </I>delivery of RNAi
therapeutics. Terms of the agreement were not disclosed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tod Woolf, Ph.D., President and Chief Executive Officer of RXi, stated, &#147;RXi&#146;s self-delivering
rxRNA&#153; (sd-rxRNA&#153;) technology platform, which is based on a combination of this technology acquired
from Advirna and RXi internally developed technology, has shown extremely promising results in
pre-clinical studies. This prompted us to acquire direct ownership of the technology instead of
merely licensing it. By combining this newly acquired technology into RXi&#146;s own portfolio and
gaining full control of the patent prosecution, we enhance the potential of obtaining broader
claims that would further strengthen RXi&#146;s intellectual property position.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The broad clinical potential of Advirna&#146;s technology in combination with RXi&#146;s rxRNA&#153; platform,
which includes sd-rxRNA&#146;s, may enable RXi to develop a robust and sustainable RNAi therapeutic
platform with significant competitive advantages in efficacy, toxicity, ease of administration and
manufacturing costs when compared to traditional RNAi compounds. The unique capabilities of this
technology are generating substantial interest in the scientific and business community.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About RNA Interference (RNAi)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Regarded as a revolutionary discovery in biology, RNA interference (RNAi) is a naturally occurring
mechanism whereby short, double-stranded RNA molecules interfere with the expression of genes in
living cells. This mechanism has the potential to be harnessed to &#147;silence&#148; or specifically block
the production of disease-causing proteins before they are made. This technology can potentially
be used to treat human diseases by &#147;turning-off&#148; genes that lead to disease in the first place. RXi
Pharmaceuticals is using RNAi technology to develop RNA-derived molecules targeting disease-causing
genes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About RXi Pharmaceuticals Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and
potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the
treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi
compounds and delivery methods. RXi uses its own version of RNAi compounds &#151; rxRNA&#153; &#151; that
provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next
generation of RNAi technology. rxRNA&#153; compounds are designed specifically for therapeutic use and
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contain many of the properties needed to move RNAi based drugs into the clinic. RXi
Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based
therapeutics market with its accomplished scientific advisors, including Dr.&nbsp;Craig Mello, recipient
of the 2006 Nobel Prize for his co-
discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong
early intellectual property position in RNAi chemistry and delivery. <u>www.rxipharma.com</u>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Advirna LLC</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Advirna LLC is a small biotechnology company, founded in 2006 by Alexey Wolfson, Ph.D. and
Anastasia Khvorova, Ph.D., RXi&#146;s Chief Scientific Officer, located in Boulder, CO. The company is
primarily focused on the discovery and development of next generation nucleotide chemistries and
formulation to enable efficient and non-toxic oligonucleotide delivery to a range of tissues.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
future expectations, plan and future development of RXi Pharmaceutical Corporation&#146;s products and
technologies. These forward-looking statements about future expectations, plans and prospects of
the development of RXi Pharmaceutical Corporation&#146;s products and technologies involve significant
risks, uncertainties and assumptions, including the risk that the development of our RNAi-based
therapeutics may be delayed or may not proceed as planned and we may not be able to complete
development of any RNAi-based product, the risk that the FDA approval process may be delayed for
any drugs that we develop, risks related to development and commercialization of products by our
competitors, risks related to our ability to control the timing and terms of collaborations with
third parties <I>and </I>the possibility that other companies or organizations may assert patent rights
that prevent us from developing our products. Actual results may differ materially from those RXi
Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals
Corporation does not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of this release.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>CONTACT:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi Pharmaceuticals<BR>
Donna Falcetti<BR>
508-929-3615<BR>
ir@rxipharma.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors<BR>
S. A. Noonan Communications<BR>
Susan Noonan<BR>
212-966-3650<BR>
susan@sanoonan.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Media<BR>
Rx Communications Group<BR>
Eric Goldman<BR>
917-322-2563<BR>
<u>egoldman@rxir.com</u>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>b77383b7738301.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b77383b7738301.gif
M1TE&.#EA/@!(`/?_`*QWL(D[CLVUSGPD@;&QK7,5>+R\N7=X<9E5G8*"?&-C
M6^[D[J5IJ>76YFX-=$M+0O'J\LJIS8]$E,*;Q+*`M91-F706>=2YUH4TBI92
MF\FFS)))E_GV^:%CI;!\LZ%EIH$LAG48>G@>?G`2=XQ`D4Y.1G-S;/?R]_KZ
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MZ/W]_7@=?5)22O_______R'Y!`$``/\`+``````^`$@```C_`*5@(B2IH,&#
M"!,JE$0(@T,,F%Q)G$BQHL4!@_X%(';#R:F/($.*'#G2220.PH0Q,@--B<N7
M,&/"'-*DPS]-%X*$L,2SI\^?0($6(13'GU%O.[*]6LJTJ5.F.\RU^"?!%JM:
M=;)JW<JUJU986FLA\;>/+*4'IM*J7<M6;0\!4R6`$F6!G]V[>//JM0MD@`B[
M%A#\(NN/S(-^B!,K7IQX%%RJ<^ONG;P72(`!0/@!D9*%,!]2C$,O=APW,N73
M>`<@*&*W2)U3A!&9"B6Z-FG(=%&CKD,(BJ>[M=P0GB&+=NW0M^7FUDW9`J<,
M(>X6>+</C#_BQH^/?JQ<,G.]16!]_R%4YVZ("L>,RLZNO3%WT]_!#S@%(K/=
M.HKN&/W<GG%R^/'AQ=L2F-U5!PC8&(7/8?TI]M]R=A7@@"X4ZF(!:Y-Y0L0D
MEF"HF13I&,4,@Z*5\,`#)3CX'H2P=*%'$#`2@4$M]NE5``63B.#A9N+X\TL"
MH(D6B@(FF*!`=@]Z5T`21C6)C0>P3%9`(TO<LN,`#?@3C2&QU%8"`;OLHH,*
M[I4&80'U&-7'/$:!@<!O>87'@AA6WK79-?[DD0(PM9%"A5$$D(E8DM+%8%0B
MA'QBE!`%@,?/!85T:"`(3UQ77)]G7'$%#H+V0VB$AOICSQ%"&&5#"!ZV)H(+
M"TA1WGUSF/_A#PXDAA8*#8880@.2*RH9J@8C3&`J+*GR4X0(D_@00)1VP4("
M(_LDT&F))W99)FZ^&@6LL/[80&R<1<CASP>-VA6"8&TH8(IV*IPX[:?\%/!K
ML,,66T0(,/B#1+GQ;N+/$/VPQY@IE/32RR76>MIKH=K2V^VW><GKSQ,@,%N+
MH89I1XH!@'8*K\3^;%NOC8#PXH\'M1A;1R)@'!!DGZL8I8K'"X/:,+?>%LM/
M"%VP2<LA(?2EAA%[:ARS/S-?VQW#(3N<LUYU2&&-4><4$$(`VS23HM$RTVQF
MMDWC#'%>GNQAU"]0.,")/Y=,*QHI1R<]:,WQSIN,MF/C54`'_IC_K(84[K1!
MP[I<(^TUMDR/BH91*Z2\5]35G(W`%(B\?!S<72L-(,BV5$"'/W!L`.=>P1E5
M"!Z[M-T?YH9K?J:A^_011AC%(,#O7K!@`($_QGRA#PUNOQWWX4O;7)8_)_QA
M![.4R>M#!<CP\<(]M0J?^=Q?,WU#(R>0%8QWN,]!`3G^W`//-#0D;'WKV"-N
MLS_G',$-U1>>!HLG9;1C"`_^!%JXW`K+WOLTH(O%A2QO>K'`!MA!@`2$P1]O
M,,'6U@?`C\U+;#K#2]G*IX/AJ(\QK*L@W4`FLH=EL%F8B`,/4J"%81S%93"[
M7@#=5[>;C4Q*6_"'`4CQ@`2@P"A4"%YB_T)(O,U=\(9ZZ4N6F/"`4#R`#T;)
MAP(^.,3AN0YL)7S:7@I@AWULJ4LE4`#__$$)(?:#B%=D6A81:)XJ^$,&X3#.
M`[Q@%`-,<#%H;%_Q:A@V)`I(=_XX`RH2$PL:3"-/*2`<'JVH1R/:T(1;#`)9
M7C"M,700#EJ@XAD9.<,]DM!I;'0-*/QQ!6W<D11:@,,^RB'$/';2D4USAQ_O
M`TA')%(QH0C%$/SAA>HAQI46U)8N2N6//;"Q`)RPS@QRN9@Y!K*5G`QFR'3Q
M!:-4H0[V"L%8D#8&QI3`!/N@0BP$MDD9?DP>1HF`+@)AE#+H*"]U&,#G_,%$
MQA0R'S^8#0A[8?^4,Q3Q3#4XP0F0,((.Q.,$X@#!J^X"BP!T#P7WL!QB0H$+
M&>23G*0@@*;P\4_O%$$@&``!/RSA$$Q8PD8?*$LT,AF:C?U@G*&A@0(40`-9
MI-%`%K!`E("04T_HK'3^6,,40_,`50C"C+%0@0K4!Z\`N28"1AG&X(A*!EHU
MJ)$0"A`0+)$#H]A2D8I1`1?*>-579C4^FWF$4=B`#G*>D1DFT*1MZ!:@.@#2
M'VRP@EM-\8)=E;6I\8$%(;J'U[8R)A16T`(NRFI6\,6'9QPPBC)NR1A<X&(=
MC/T/*PI0A,YZ]K.@_:P%*L`F?TPC!>/,I6IS.9O5NO:UN;R-)D#!`%W_%."V
MN,VM;G.KBPWTP2AKH,$#4$'<XAKWN,A%[ENF$@`LB"$9K8BN=*=+W>E.0`X<
MZ$,?I&&`;J3BN^`-KWC'.UY$/(,(_SA$&CCA"U:X][WPC6]\&3"+^LZB%/C-
MKW[WR]_^XK<+'_A'`R+QB0(;^,`(3K""%\S@!A?X!D_X1Y,F3.$*6_C"&,XP
MAO^QCPY[^,,@#K&(1TSB$H=8PFTRRO'(LN*R@,'$,!:QBD/,XGV@6,5-^H6'
M*QSC'A\O#"*VCH?_\8X/=``&N?``!`!P@2WL+AF#8,`DM@`)#5N9PHD@Q@26
M4&%:^*%)_Q@!"^PQ`%M@@@$D:("3_:$.!E!`_Q%S\(`&[K"$%6"A`<^0PQ*J
M4`47P"`.%UB!&N[0"A;T80E"2,<GLD`,6RAB&2OXQB>^`(D%-,()WY`"'9)`
MAW^(8!$KD,`=W*"+""P@`"'J0!`H$`!%#`(#28AR!?P@A2TH`@H@&`0F:C"(
M#R!`#QGH@@<VT`%U9``)>K"#!!@`!0]D8A!XV$(E2&`,$F2"%38100?P@(!]
M?,$!H%@`!CKSC@``X@*:6$(PZ-$*!DC"%X"8!PF6@``6,"`0$_@`(4CP!VR\
M&0!XJ(`]`%`#3E2!%1M`P#QRD(LM!,`/DF!`&B+PCR@L(!V'R$$G\)`!8F!"
MK5`PAC]00(AQ0"$8&YA(1A=\X0=Y_R$#$6!`!2KP!0EHP@81&,0&+E"/"J#A
M'5L@0B.>4X$&4*`+;L"#'P)0!3?<XA]S6``$-O`!(F"C"T*H`"W\L0DFG2`#
M+@`'!:B1A@P`8`O'`'L'$N$'/4A"'7@0@B(D<0$\**(>QL``-82P!4TX0PAI
AP`0`@K"!"G@@`[,@A"_^P?C&._[QD(^\Y"=/><D'!``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
